ArticleFrontiers in cardiovascular medicine2026
Regional and racial outcomes in mortality after atrial fibrillation ablation in medicare Fee for service patients.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Catheter ablation of Atrial Fibrillation (AF) is a cornerstone of treatment. Data on regional and racial variations in AF ablation procedural mortality are limited. Methods: Data were abstracted from the 2016-2019 Medicare Fee for Service database (FFS), including inpatient and outpatient visits to evaluate regional and racial differences in 30-day AF ablation mortality in Medicare FFS patients. Patients with an AF diagnosis who had AF ablation were identified via ICD-10, CPT, and MS-DRG codes. The primary outcome was between-region (Northeast, Midwest, South, West) differences in 30-day mortality which was assessed using logistic regression models; multivariable models controlled for race, comorbid COPD, and CHA2DS2-VASc score. Results: 38,477 inpatient and 128,544 outpatient AF ablations met inclusion criteria. AF ablation was most common in the South (inpatient: 17,415, outpatient: 55,932) and least in the Northeast which had a 28% lower adjusted odds of 30-day mortality following inpatient AF ablation compared to the South (NE: 1.75.% vs. S: 2.55%; aOR: 0.72, 95% CI: 0.60-0.88) and 23% lower adjusted odds compared to the West (NE: 1.75% vs. W: 2.30%; aOR: 0.81, 95% CI: 0.66-0.99). In outpatients, the Northeast had 44% lower adjusted odds of 30-day mortality compared to the West (NE: 0.15% vs. W:0.25%; aOR 0.56, 95% CI: 0.36-0.87) and the West had a 73% greater odds of 30-day mortality compared to the South (W: 0.25% vs. S: 0.16%; aOR: 1.73, 95% CI: 1.27-2.36). Non-white patients had higher mortality in the outpatient cohort. Conclusions: Within this Medicare FFS population, significant variations in mortality exist following AF ablation when analyzed across different regions and race. Further research on potential systemic and patient level factors would be of value to help elucidate why these differences are present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.